Early Studies Show EBTATE is Well Tolerated and Effective in Treating Neuroendocrine Tumors

Molecular Targeting Technologies, Inc. (MTTI) announced today that
Professor Zhaohui Zhu et. al. of the Department of Nuclear Medicine,
Peking Union Medical College Hospital (PUMC), Beijing, China will
present a talk entitled “Safety and Response of an Evans
Blue-modified ¹⁷⁷Lu-labeled Octreotate (EBTATE)
in Treatment of Metastatic Neuroendocrine Tumors: A Pilot Prospective
Study” at the Society of Nuclear Medicine and Molecular Imaging
(SNMMI) in Anaheim this June*.

This press release features multimedia. View the full release here:
https://www.businesswire.com/news/home/20190624005007/en/

Partial Remission of Bone and Lymph Node Metastases After One Cycle of EBTATE (PRRT-peptide receptor radionuclide therapy). (Graphic: Business Wire)

MTTI received an exclusive worldwide commercialization license from NIH
for this technology. This patent estate covers our EBTATE
radiotherapeutic. Neuroendocrine neoplasm (NEN) treatment is among its
potential uses.

The talk describes results of a dose escalation study comparing MTTI’s
EBTATE to Lutathera®. EBTATE was designed to have prolonged circulation
half-life and increased neuroendocrine tumor accumulation versus its
predecessor. Dr. Zhu’s team studied 26 patients in three groups with
metastatic neuroendocrine neoplasms (NENs), comparing two dose levels of
EBTATE to Lutathera® against Common Toxicity Criteria (CTC) for
tolerability.

Qingxing Liu and Zhaohui Zhu highlighted, “One treatment cycle of 1.85
GBq (50 mCi) or 3.70 GBq (100 mCi) of EBTATE seems to be well tolerated
and more effective than 3.70 GBq (100 mCi) of Lutathera®.”

“Based on this early work, EBTATE could be the next, more effective,
innovation in radiolabeled molecules for NEN. We’re excited about this
breakthrough and thank PUMC’s colleagues for their exceptional
contribution in our concerted effort to develop this robust therapy,”
said Chris Pak, President & CEO of MTTI.

MTTI is a privately held biotechnology company focused on the
acquisition and development of novel technologies for treatment and
diagnosis of human diseases. More information: www.mtarget.com.

*Oral presentation by Qingxin Liu, Zhaohui Zhu and Xiaoyuan Chen
et. al.

TATE: Lutathera®; EBTATE: MTTI’s EBTATE;
CR: Complete response; PR:
partial response; SD: stable disease; PD: progressive disease

View source version on businesswire.com: https://www.businesswire.com/news/home/20190624005007/en/